Cure CMD (Congenital Muscular Dystrophy) logo
Cure CMD International Research Grants

Cure CMD Congenital Dystroglycanopathies Research Grant

Funds accredited research institutions developing treatments for congenital dystroglycanopathies with grants up to $50,000.

ClosedCure CMD (Congenital Muscular Dystrophy)GlobalDeep-tech · core fit

Eligibility · Global — no geographic restrictions

Cure CMD administers this international research grant under its 2026 Request for Applications for congenital muscular dystrophy. It provides up to USD 50,000 for one or two years of work on congenital-onset alpha-dystroglycanopathies. The funded work can cover the causes of the disease, new treatment targets, gene-based and platform approaches, preclinical testing, disease models, biomarkers and

Research on congenital dystroglycanopathy disease mechanisms, muscle and brain effects, treatment targets, gene-based approaches, disease models, biomarkers and trial-readiness tools.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.No fixed schedule
Next deadlineiThe next date applications are due. Rolling means you can apply any time.14 Sept 2026
Decision timeiTypical time from the deadline to the funder's decision.
Project durationiHow long the funded work is expected to run.12–24 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.
Funding pooliThe total budget available across all awards in this round.

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 4 Aug 2026Source: www.curecmd.org